Psychedelics are challenging the standard of randomized controlled trials
Psychedelic-assisted therapies are raising hard questions about how to evaluate treatments whose effects are deeply subjective, obvious to participants, and tightly bound to context, making traditional double‑blind randomized controlled trials difficult or impossible to run cleanly. Commenters argue over whether entities encountered on drugs like DMT are purely brain-generated hallucinations or could indicate something more, but most converge on the view that vivid altered states can still be therapeutically useful even if entirely internal. The thread also highlights high placebo response rates in mental health, the need for better trial design and use of contextual factors (set and setting), and real risks such as triggering psychosis in vulnerable people.
Reality of Psychedelic Entities
- Major subthread on whether DMT/LSD entities are “external beings” or brain-generated.
- Skeptical side:
- Hallucinations also occur in fever, alcohol withdrawal, dreams, brain stimulation.
- No physical evidence of extra entities; would require new physics or a new undetected force.
- Similar reports across users can be explained by similar brains, shared culture/mythology, and suggestibility.
- More open/agnostic side:
- Personal experiences feel overwhelmingly “real,” leaving some with residual doubt.
- Argues it’s premature to rule out non-material entities given current limits of neuroscience and consciousness research.
- Some invoke frameworks like bicameral mind theory, internal family systems, and “talking to the subconscious” rather than literal external beings.
Therapeutic Potential and Risks of Psychedelics
- Multiple commenters report genuine psychological benefits (PTSD, depression, trust issues, alcoholism), often attributed to:
- Access to new perspectives.
- Emotional “debug mode.”
- Internalizing insights rather than learning new facts.
- Others stress serious risks:
- Triggering earlier onset of schizophrenia in predisposed individuals.
- Persistent derealization, HPPD, or psychotic breaks.
- Rare but extreme “dark trips,” especially at very high doses or poor set/setting.
- Emphasis that different psychedelics (LSD, psilocybin, DMT, peyote, MDMA) and doses produce very different profiles.
Placebo Effect, Faith, and Clinical Trials
- Strong agreement that mental-health trials have unusually large placebo responses; hence need for careful controls.
- Placebo described as:
- Real symptom relief (especially for pain, mood) without fixing underlying pathology.
- Closely related to expectation, hope, and “magical thinking,” but not limited to religious faith.
- Debate on whether placebo is “just noise” vs a powerful therapeutic tool that should be actively harnessed.
- Nocebo effects (harm from negative expectations) and optimism’s impact on health outcomes are discussed.
RCTs, Psychedelics, and Trial Design
- Core challenge: blinding is hard when participants know they’re tripping; standard double-blind RCT assumptions break.
- Some argue RCT “absolutism” is overdone, especially for fatal diseases; others insist RCTs remain essential to avoid bias and overhyped treatments.
- Suggested mitigations: active placebos (e.g., niacin), different statistical approaches, and considering context/therapy as part of the treatment rather than “noise.”
Transcendence and Meaning
- Several argue that the mystical/transcendent quality of trips may be central to antidepressant effects.
- Linked to broader loss of rituals and meaning in modern life; psychedelics may temporarily restore a sense of awe and purpose, which standard pharmacology often ignores.